CervoMed Inc. (CRVO)
NASDAQ: CRVO
· Real-Time Price · USD
7.55
0.01 (0.13%)
At close: Jun 06, 2025, 3:59 PM
7.69
1.79%
After-hours: Jun 06, 2025, 05:22 PM EDT
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.
It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.
The company is based in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Dr. John J. Alam M.D. |
Contact Details
Address: 20 Park Plaza Boston, Massachusetts United States | |
| Website | https://www.cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer & Director |
| William Robert Elder J.D. | Chief Financial Officer, General Counsel & Corporate Secretary |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. Mark A. De Rosch Ph.D. | Executive Vice President of Regulatory, Government Affairs & Program Management |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | 3 | Filing |
| May 19, 2025 | 8-K | Current Report |
| May 14, 2025 | 4 | Filing |
| May 12, 2025 | 424B5 | Filing |
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 07, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 18, 2025 | 8-K | Current Report |